Tewksbury, Massachusetts-based Corvia designed its shunt for heart failure patients with preserved (HFpEF) or mildly reduced (HFmrEF) ejection fraction.
Dr. Scott Lilly and Dr. Rami Kahwash enrolled and randomized the first patient at the Ohio State University Wexner Medical Center. In a news release, Lilly noted that atrial shunt therapy could “represent significant clinical benefit” for millions of patients.
“Despite ongoing pharmaceutical advances, the treatment of HFpEF remains challenging, and multiple therapies are needed to treat such a heterogenous disease,” said Kahwash. “We are pleased to offer access to a novel treatment option that has the potential to relieve our patients’ breathlessness and improve their quality of life.”
About Responder-HFC…